Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $30 | In Stock | |
2 mg | $40 | In Stock | |
5 mg | $64 | In Stock | |
10 mg | $106 | In Stock | |
25 mg | $176 | In Stock | |
50 mg | $262 | In Stock | |
100 mg | $389 | In Stock | |
500 mg | $882 | In Stock | |
1 mL x 10 mM (in DMSO) | $43 | In Stock |
Description | Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain. |
In vivo | Pivagabine (CXB 722) (200 mg/kg; i.p.; administered twice daily for 4 days and 1 hour before euthanasia on the 5th day) prevents foot-shock stress-induced changes in CRF concentration in both brain regions[2]. |
Animal Research | Pivagabine (CXB 722) (200 mg/kg; i.p.; twice a day for 4 days and 1 hour before killing on the 5th day) prevents the effects of foot-shock stress on CRF concentration in both brain regions, reduced by 52% the CRF concentration in the hypothalamus but had no effect on that in the cerebral cortex[2]. |
Alias | CXB-722 |
Molecular Weight | 187.24 |
Formula | C9H17NO3 |
Cas No. | 69542-93-4 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 45 mg/mL (240.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.